{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Other+Lung+Disease&page=4", "query": { "condition": "Other Lung Disease", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 251, "total_pages": 26, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Other+Lung+Disease&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Other+Lung+Disease&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T18:31:27.495Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05512377", "title": "Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Neoplasms", "Solid Tumors", "Biliary Tract Cancer", "Lung Neoplasms", "Bladder Cancer" ], "interventions": [ { "name": "brigimadlin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 99, "start_date": "2022-12-13", "completion_date": "2025-09-25", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-10-09T18:31:27.495Z", "location_count": 18, "location_summary": "Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 14 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Rosa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05512377" }, { "nct_id": "NCT03329950", "title": "A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Non-small Cell Lung Cancer", "Breast Cancer", "Gastric Cancer", "Renal Cell Carcinoma", "Ovarian Cancer", "Cholangiocarcinoma", "Bladder Urothelial Carcinoma", "Pancreatic Adenocarcinoma", "Colorectal Cancer", "Esophageal Cancer", "Hepatic Cancer", "Head and Neck Cancer", "Primary Peritoneal Cancer", "Fallopian Tube Cancer", "Other Solid Tumors", "Diffuse Large B-cell Lymphoma (DLBCL)", "Mantle Cell Lymphoma", "Indolent B-cell Lymphomas", "Non-Hodgkin Lymphoma", "Follicular Lymphoma", "Lymphoplasmacytic Lymphoma", "Waldenstrom's Disease", "Marginal Zone Lymphoma", "Mucosa Associated Lymphoid Tissue", "Small Lymphocytic Leukemia" ], "interventions": [ { "name": "CDX-1140", "type": "DRUG" }, { "name": "CDX-301", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 132, "start_date": "2017-12-01", "completion_date": "2022-09-13", "has_results": false, "last_update_posted_date": "2024-03-28", "last_synced_at": "2026-10-09T18:31:27.495Z", "location_count": 11, "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Augusta, Georgia + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03329950" }, { "nct_id": "NCT03261947", "title": "A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Cancer", "Colorectal Cancer", "Esophageal Neoplasms", "Carcinoma, Non-small-cell Lung" ], "interventions": [ { "name": "TAK-931", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 101, "start_date": "2017-10-25", "completion_date": "2020-08-24", "has_results": true, "last_update_posted_date": "2021-09-20", "last_synced_at": "2026-10-09T18:31:27.495Z", "location_count": 8, "location_summary": "Denver, Colorado • Sarasota, Florida • Minneapolis, Minnesota + 5 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT03261947" }, { "nct_id": "NCT07094113", "title": "AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "KRAS Altered Advanced or Metastatic Solid Tumors" ], "interventions": [ { "name": "AMG 410", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Panitumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 434, "start_date": "2025-07-31", "completion_date": "2031-04-20", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-10-09T18:31:27.495Z", "location_count": 10, "location_summary": "Duarte, California • Los Angeles, California • Atlanta, Georgia + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07094113" }, { "nct_id": "NCT04244552", "title": "A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Colorectal Cancer", "Ovarian Cancer", "Non-Small Cell Lung Cancer", "Acral Lentiginous Melanoma", "Head and Neck Squamous Cell Carcinoma", "Hepatocellular Carcinoma", "Esophageal Squamous Cell Carcinoma", "Urothelial Carcinoma", "DMMR Colorectal Cancer", "MSI-H Colorectal Cancer", "Melanoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Epithelial Ovarian Cancer", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "ATRC-101", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pegylated liposomal doxorubicin (PLD)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Atreca, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2020-02-11", "completion_date": "2023-11-01", "has_results": false, "last_update_posted_date": "2023-12-29", "last_synced_at": "2026-10-09T18:31:27.495Z", "location_count": 19, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Duarte, California + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04244552" }, { "nct_id": "NCT05483491", "title": "KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastric Cancer", "Breast Cancer", "Cervical Cancer", "Lung Cancer" ], "interventions": [ { "name": "KK-LC-1 TCR-T cells", "type": "BIOLOGICAL" }, { "name": "Aldesleukin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Christian Hinrichs", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2022-09-26", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-09T18:31:27.495Z", "location_count": 2, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05483491" }, { "nct_id": "NCT07111520", "title": "A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "BNT326", "type": "DRUG" }, { "name": "Pumitamig", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 880, "start_date": "2025-09-22", "completion_date": "2030-06", "has_results": false, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-10-09T18:31:27.495Z", "location_count": 11, "location_summary": "Los Angeles, California • Stanford, California • New Haven, Connecticut + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07111520" }, { "nct_id": "NCT05619744", "title": "A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Small Cell Lung Cancer", "Neuroendocrine Carcinoma" ], "interventions": [ { "name": "RO7616789", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2023-01-23", "completion_date": "2025-03-04", "has_results": false, "last_update_posted_date": "2025-03-10", "last_synced_at": "2026-10-09T18:31:27.495Z", "location_count": 10, "location_summary": "Washington D.C., District of Columbia • Boston, Massachusetts • Detroit, Michigan + 7 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05619744" }, { "nct_id": "NCT06726148", "title": "Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced HR+/HER2- Breast Cancer", "Advanced CCNE1-amplified Solid Tumors", "Extensive-stage Small Cell Lung Cancer" ], "interventions": [ { "name": "ECI830", "type": "DRUG" }, { "name": "ribociclib", "type": "DRUG" }, { "name": "fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 280, "start_date": "2025-04-03", "completion_date": "2028-09-25", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-10-09T18:31:27.495Z", "location_count": 8, "location_summary": "Los Angeles, California • Fort Myers, Florida • Boston, Massachusetts + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06726148" }, { "nct_id": "NCT02648178", "title": "Evaluation of Appeal and Impact of E-Cigarettes Among Chronic Smokers With Smoking-Related Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Nicotine Dependence, Other Tobacco Product", "Bladder Cancer", "Lung Cancer", "Cancer of Head and Neck" ], "interventions": [ { "name": "HALO", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2016-06", "completion_date": "2018-05", "has_results": true, "last_update_posted_date": "2019-09-19", "last_synced_at": "2026-10-09T18:31:27.495Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT02648178" } ] }